Title & Introduction

  • Paper Title: Personal and Social Connection to Psychedelics is Associated with Lower Drug Use Stigma Among Psychiatrists in the United States
  • Published In: Journal of Psychedelic Studies
  • Publish Date: September 17, 2024
  • Authors: Adam W. Levin, Aryan Sarparast, Paul Nagib, Alan K. Davis
  • Objective: To examine how personal and social connections to psychedelics among U.S. psychiatrists influence their attitudes toward drug use and people who use drugs.
  • Importance: Stigma towards drug users remains a significant barrier to treatment access and engagement. Understanding how firsthand experience with psychedelics impacts psychiatrists’ perceptions could inform efforts to reduce stigma in psychiatric practice.

Summary & Takeaways

Key Takeaway: Psychiatrists with personal or social experience with psychedelics displayed significantly lower stigma towards drug use and drug users compared to those with no such connections.

Practical Application: These findings suggest that increasing exposure to education and personal narratives about psychedelics could help reduce stigma among healthcare providers, potentially improving care for individuals with substance use disorders.

Key Background Information

  • Context: Stigma among healthcare professionals is a major factor preventing people with substance use disorders (SUD) from seeking treatment.
  • Hypothesis: Psychiatrists with personal or social connections to psychedelics would report lower levels of drug-related stigma compared to those without such experiences.

Methodology

  • Study Design: Cross-sectional survey study.
  • Participants: 180 U.S. psychiatrists recruited via email lists and personal networks.
  • Intervention/Exposure: Participants were categorized into three groups: No Connection (NC), Social Connection (SC), and Personal Connection (PC) to psychedelics.
  • Controls: None; comparisons were made between groups based on responses.
  • Duration: Data collection occurred from April to May 2021.

Key Findings

Primary Outcomes:

  • 32.8% of psychiatrists had a Personal Connection to psychedelics.
  • Those with Personal or Social Connection were more likely to disagree with statements endorsing stigma, including:
    • "Illegal drug users should go to prison" (p < 0.001, ηp2 = 0.15)
    • "Illegal drug users are weak-minded" (p < 0.001, ηp2 = 0.10)
    • "Illegal drug users have no future" (p < 0.001, ηp2 = 0.12)
  • Psychiatrists with a Personal Connection rated psilocybin as:
    • Safer than other psychiatrists (p < 0.001, ηp2 = 0.31)
    • Having lower abuse potential (p < 0.001, ηp2 = 0.24)
    • Having greater therapeutic potential (p < 0.001, ηp2 = 0.33)

Secondary Outcomes:

  • No significant differences in attitudes toward alcohol, methamphetamine, or ketamine were observed between groups.
  • Psychiatrists with Personal Connection were more likely to support the therapeutic use of psilocybin.
  • Younger psychiatrists and those in training were more likely to have a Personal Connection to psychedelics.

Interpretation & Implications

  • Conclusion: Personal and social exposure to psychedelics correlates with reduced drug-related stigma among psychiatrists, potentially influencing treatment approaches and policy perspectives.
  • Implications: Psychedelic education and exposure to firsthand narratives may help reduce stigma in psychiatric training and practice, improving patient care.
  • Limitations: Self-reported data, potential selection bias, and lack of racial/ethnic demographic data limit generalizability.

Researchers & Publication

Share this post